Novartis heaps pressure on Lilly with broad FDA approval for Kisqali in early breast cancer

An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early breast cancer.

The FDA has greenlighted Novartis’ Kisqali, used in combination with an aromatase inhibitor, for the adjuvant treatment of HR-positive, HER2-negative stage 2 and 3 breast cancer that’s at high risk of recurrence following surgery, the company said Tuesday.